Tabira Takeshi, Matsumoto Shin-Ei, Jin Haifeng
Department of Diagnosis, Prevention and Treatment of Dementia, Graduate School of Medicine, Juntendo University.
Rinsho Shinkeigaku. 2011 Nov;51(11):1160-1. doi: 10.5692/clinicalneurol.51.1160.
In order to avoid Abeta-induced autoimmune encephalitis, several monoclonal and polyclonal antibodies are in clinical trials. These are bapineuzumab, solanezumab, ponezumab, gantenerumab, BAN2401, gammaguard and octagam. Since each antibody has a different antigen epitope of Abeta, anti-amyloid activities are different. It is unknown which antibody is effective for Alzheimer disease, and we must wait for the result of clinical trials. Some patients who developed tissue amyloid plaque immuno-reactive (TAPIR) antibody showed slower decline after AN-1792 vaccination. We developed TAPIR-like monoclonal antibody, which was found to react with Abeta oligomers preferentially.
